Skip to content

An observational study on protein profiling of atherosclerotic plaque tissues in patients undergoing internal carotid endarterectomy by mediating macrophage foaming with a-Syn through LAG3 receptor

An observational study on protein profiling of atherosclerotic plaque tissues in patients undergoing internal carotid endarterectomy by mediating macrophage foaming with a-Syn through LAG3 receptor

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120369
Enrollment
Unknown
Registered
2026-03-13
Start date
2026-03-14
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Interventions

Atherosclerotic group:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged >=18 years and <= 80 years, regardless of gender. 2.Meet the above diagnostic criteria for internal carotid artery stenosis, and have a clear plan to undergo Carotid Endarterectomy (CEA) after evaluation by a vascular surgeon. 3.Voluntarily sign the informed consent form, agree to participate in this study, and authorize the researchers to use the atherosclerotic plaque tissue resected during the operation and clinical data for research purposes. 4.No severe dysfunction of vital organs such as heart, lung, liver or kidney, and be able to tolerate CEA surgery. 5.Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3 times the upper limit of normal reference range; Renal function: serum creatinine (Scr) <= 1.5 times the upper limit of normal reference range; Coagulation function: international normalized ratio (INR) <=1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) within the normal reference range. 6. No severe dysfunction of vital organs such as the heart, lungs, liver, or kidneys, and able to tolerate CEA surgery.

Exclusion criteria

Exclusion criteria: 1.Patients with malignant tumors (regardless of treatment status, with an expected survival time of 2 points) within the recent 3 months.

Design outcomes

Primary

MeasureTime frame
peptide;

Countries

China

Contacts

Public ContactLing Mao

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

maoling13096@163.com+86 151 7231 4891

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026